# High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML

> **NCT00474006** · PHASE3 · COMPLETED · sponsor: **Cooperative Study Group A for Hematology** · enrollment: 398 (actual)

## Conditions studied

- ACUTE MYELOGENOUS LEUKEMIA

## Interventions

- **DRUG:** arm II

## Key facts

- **NCT ID:** NCT00474006
- **Lead sponsor:** Cooperative Study Group A for Hematology
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2008-08
- **Final completion:** 2010-04
- **Target enrollment:** 398 (ACTUAL)
- **Last updated:** 2011-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00474006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00474006, "High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00474006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*